Table 2.
Observations | Before PS Matched | After PS Matched | ||||
---|---|---|---|---|---|---|
Historical Control Group (n=177) | Technical Improvement Group (n=281) | P -value | Historical Control Group (n=143) | Technical Improvement Group (n=143) | P -value | |
Pain (score) | 0 (1.0) | 0 (0) | P<0.001 | 0 (1.0) | 0 (0) | P<0.001 |
No pain | 113 | 233 | P<0.001 | 90 | 123 | P<0.001 |
Mild pain | 49 | 42 | 42 | 18 | ||
Moderate or higher pain | 15 | 6 | 11 | 2 | ||
Skin numbness | 63 (35.6%) | 22 (7.8%) | P<0.001 | 52 (36.4%) | 11 (7.7%) | P<0.001 |
Persistent exudation | 21 (11.9%) | 38 (13.5%) | 0.606 | 14 (9.8%) | 21 (14.7%) | 0.207 |
Edema | 42 (23.7%) | 44 (15.7%) | 0.031 | 28 (19.6%) | 23 (16.1%) | 0.440 |
Subeschar healing | 9 (5.1%) | 1 (0.4%) | 0.001 | 7 (4.9%) | 1 (0.7%) | 0.066 |
Infection or rupture | 7 (4.0%) | 2 (0.7%) | 0.031 | 3 (2.1%) | 1 (0.7%) | 0.622 |
Abbreviation: PS, propensity score.